Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 13, Issue 5, Pages 273-290Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2016.25
Keywords
-
Categories
Funding
- American Association for Cancer Research Amgen fellowship in Clinical/Translational Cancer Research
- American Philosophical Society Daland Fellowship in Clinical Investigation
- Conquer Cancer Foundation of ASCO
- Lymphoma Research Foundation
- MSKCC Technology Development Fund
- Multiple Myeloma Research Foundation
- Annual Terry Fox Run for Cancer Research (New York, NY)
- Carson Family Charitable Trust
- Emerald Foundation
- Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center (Innovations in the structures, functions and targets of monoclonal antibody-based drugs for cancer)
- Kate's Team
- National Institutes of Health [R01CA138738-05, PO1CA059350, PO1CA190174-01]
- William Lawrence and Blanche Hughes Foundation
- Bristol-Myers Squibb
- Genentech
- Ludwig Center for Cancer Immunotherapy
- Medimmune
- Merck Pharmaceuticals
- Polynoma Pharmaceuticals
- Swim Across America
Ask authors/readers for more resources
In the past decade, advances in the use of monoclonal antibodies (mAbs) and adoptive cellular therapy to treat cancer by modulating the immune response have led to unprecedented responses in patients with advanced-stage tumours that would otherwise have been fatal. To date, three immune-checkpoint-blocking mAbs have been approved in the USA for the treatment of patients with several types of cancer, and more patients will benefit from immunomodulatory mAb therapy in the months and years ahead. Concurrently, the adoptive transfer of genetically modified lymphocytes to treat patients with haematological malignancies has yielded dramatic results, and we anticipate that this approach will rapidly become the standard of care for an increasing number of patients. In this Review, we highlight the latest advances in immunotherapy and discuss the role that it will have in the future of cancer treatment, including settings for which testing combination strategies and 'armoured' CAR T cells are recommended.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available